Cost-of-illness analysis and regression modeling in cystic
fibrosis: a retrospective prevalence-based study

J 2017

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

MLČOCH, Tomáš; Jiří KLIMEŠ; Libor FILA; Věra VÁVROVÁ; Veronika SKALICKÁ et. al.

Základní údaje

Originální název

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Autoři

Vydání

EUROPEAN JOURNAL OF HEALTH ECONOMICS, NEW YORK, SPRINGER, 2017, 1618-7598

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

50200 5.2 Economics and Business

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.601

Kód RIV

RIV/00216224:14110/17:00096876

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s10198-015-0759-9

UT WoS

000392437100007

EID Scopus

2-s2.0-84953410327

Klíčová slova anglicky

Cystic fibrosis; Cost-of-illness; Disease severity; Health care costs; FEV1; Generalized linear model

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 16:04, Soňa Böhmová

Anotace

V originále

Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were a,notsign14,486 per patient, with the majority of the costs going towards medicinal products and devices (a,notsign10,321). Medical procedures (a,notsign2676) and inpatient care (a,notsign1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.

Citovat

MLČOCH, Tomáš; Jiří KLIMEŠ; Libor FILA; Věra VÁVROVÁ; Veronika SKALICKÁ; Marek TURNOVEC; Veronika KRULIŠOVÁ; Jitka JIRČÍKOVÁ; Dana ZEMKOVÁ; Klára VILIMOVSKÁ DĚDEČKOVÁ; Alena BÍLKOVÁ; Vladimíra FRÜHAUFOVÁ; Lukáš HOMOLA; Zuzana FRIEDMANNOVÁ; Radovan DRNEK; Pavel DŘEVÍNEK; Tomáš DOLEŽAL a Milan MACEK. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. EUROPEAN JOURNAL OF HEALTH ECONOMICS. NEW YORK: SPRINGER, 2017, roč. 18, č. 1, s. 73-82. ISSN 1618-7598. Dostupné z: https://doi.org/10.1007/s10198-015-0759-9.

@article{1382080,
   author = {Mlčoch, Tomáš and Klimeš, Jiří and Fila, Libor and Vávrová, Věra and Skalická, Veronika and Turnovec, Marek and Krulišová, Veronika and Jirčíková, Jitka and Zemková, Dana and Vilimovská Dědečková, Klára and Bílková, Alena and Frühaufová, Vladimíra and Homola, Lukáš and Friedmannová, Zuzana and Drnek, Radovan and Dřevínek, Pavel and Doležal, Tomáš and Macek, Milan},
   article_location = {NEW YORK},
   article_number = {1},
   doi = {https://doi.org/10.1007/s10198-015-0759-9},
   keywords = {Cystic fibrosis; Cost-of-illness; Disease severity; Health care costs; FEV1; Generalized linear model},
   language = {eng},
   issn = {1618-7598},
   journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
   title = {Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study},
   volume = {18},
   year = {2017}
}

TY  - JOUR
ID  - 1382080
AU  - Mlčoch, Tomáš - Klimeš, Jiří - Fila, Libor - Vávrová, Věra - Skalická, Veronika - Turnovec, Marek - Krulišová, Veronika - Jirčíková, Jitka - Zemková, Dana - Vilimovská Dědečková, Klára - Bílková, Alena - Frühaufová, Vladimíra - Homola, Lukáš - Friedmannová, Zuzana - Drnek, Radovan - Dřevínek, Pavel - Doležal, Tomáš - Macek, Milan
PY  - 2017
TI  - Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
JF  - EUROPEAN JOURNAL OF HEALTH ECONOMICS
VL  - 18
IS  - 1
SP  - 73-82
EP  - 73-82
PB  - SPRINGER
SN  - 16187598
KW  - Cystic fibrosis
KW  - Cost-of-illness
KW  - Disease severity
KW  - Health care costs
KW  - FEV1
KW  - Generalized linear model
N2  - Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were a,notsign14,486 per patient, with the majority of the costs going towards medicinal products and devices (a,notsign10,321). Medical procedures (a,notsign2676) and inpatient care (a,notsign1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.
ER  -

MLČOCH, Tomáš; Jiří KLIMEŠ; Libor FILA; Věra VÁVROVÁ; Veronika SKALICKÁ; Marek TURNOVEC; Veronika KRULIŠOVÁ; Jitka JIRČÍKOVÁ; Dana ZEMKOVÁ; Klára VILIMOVSKÁ DĚDEČKOVÁ; Alena BÍLKOVÁ; Vladimíra FRÜHAUFOVÁ; Lukáš HOMOLA; Zuzana FRIEDMANNOVÁ; Radovan DRNEK; Pavel DŘEVÍNEK; Tomáš DOLEŽAL a Milan MACEK. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. \textit{EUROPEAN JOURNAL OF HEALTH ECONOMICS}. NEW YORK: SPRINGER, 2017, roč.~18, č.~1, s.~73-82. ISSN~1618-7598. Dostupné z: https://doi.org/10.1007/s10198-015-0759-9.

Přehled o publikaci